Publications

Filter by year

Filter by type

Filter by year

2021

Disease burden and patient needs/benefits in patients with psoriasis with and without anogenital involvement: Preliminary results from the PsoGen study

N. da Silva, M. Augustin, D. Wilsmann-Theis, P. Staubach-Renz, C. von Stülpnagel (2021, September-October).

ePoster presented at 30th European Academy of Dermatology and Venereology (EADV) Congress [Virtual]

Disease severity and patient needs/benefits in genital psoriasis: Patient-reported improvement after 6±1 months of Apremilast treatment

N. da Silva, R. Sommer, L. Mellars, C. von Stülpnagel, M. Cordey, M. Augustin (2021, November)

ePoster presented at 13th International Congress of Dermatology (ICD 2021) [Virtual].

Effectiveness of a structured short intervention against stigmatisation in chronic visible skin diseases: Results of a controlled trial in future educators

N-A. Weinberger MSc1, S. Mrowietz2, C. Luck‐Sikorski Prof, Dr1, R. von Spreckelsen Dr3, S. M. John Prof, Dr4, R.Sommer MPH, Dr5, M. Augustin Prof, Dr5, U.Mrowietz Prof, Dr3

1Research Group: Chronic Diseases and Psychological Health (COPE), University of Applied Health Sciences SRH Gera, Gera, Germany

2Vocational College for Social Pedagogy, RBZ Koenigsweg, Kiel, Germany

3Psoriasis‐Center at the Department of Dermatology, University Medical Center Schleswig‐Holstein, Campus Kiel, Kiel, Germany

4Department of Dermatology, Environmental Medicine, Health Theory, Institute for Interdisciplinary Dermatological Prevention and Rehabilitation (iDerm), University of Osnabrueck, Osnabrueck, Germany

5Institute for Health Services Research in Dermatology and Nursing (IVDP), German Center for Health Services Research in Dermatology (CVderm), University Medical Center Hamburg‐Eppendorf (UKE), Hamburg, Germany

Health Expect. 2021 Oct;24(5):1790-1800

 

Chronic visible skin diseases are highly prevalent, and patients affected frequently report feeling stigmatised. Interventions to reduce stigmatisation are rare.

Objectives: This study aimed to evaluate the effectiveness of a structured short intervention in reducing stigmatising attitudes towards psoriasis in future educators.

PMID:
Epub 2021 Jul 27. 34318568
DOI:
10.1111/hex.13319

Secukinumab effects on patient reported outcomes in plaque psoriasis across Europe: Data from the PROSE study

N. da Silva, R. Sommer, C-E. Ortmann, P. Jagiello, T. Bachhuber, M. Augustin (2021, July). 

 

 

ePoster presented at 6th World Psoriasis & Psoriatic Arthritis Conference [Virtual].

Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases - a systematic review

C.C. von Stülpnagel, M. Augustin, L. Düpmann, N. da Silva , R. Sommer

German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany

 J Eur Acad Dermatol Venereol. 2021 Nov;35(11):2166-2184

 

Patients with chronic skin diseases suffer from physical and psychosocial impairments which can lead to a cumulative life-long burden. Therefore, the concept of cumulative life course impairment (CLCI) was introduced, referring to the non- reversible damage due to the persistent life-long burden. This systematic review (PROSPERO registry number: CRD42020179141) aimed at mapping the risk factors and the associated burden over time in patients with psoriasis, ato- pic dermatitis (AD) and hidradenitis suppurativa (HS).

PMID:
Epub 2021 Jun 25. 33988873
DOI:
10.1111/jdv.17348

Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: patient perspective data from the PROSE study

N. da Silva1, R. Sommer1, C.-E. Ortmann2, P. Jagiello2, T. Bachhuber2, M. Augustin1

1Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany

2Novartis Pharma AG, Basel, Switzerland

J Eur Acad Dermatol Venereol. 2021 Nov;35(11):2241-2249

 

Cross-cultural differences in healthcare policies and patient–physician communication may influence the quality of care and patients’ perceived benefits and satisfaction with psoriasis treatment.

PMID:
Epub 2021 Jul 31. 34273904
DOI:
10.1111/jdv.17525

Validation of the Spanish Wound-QoL Questionnaire.

E. Conde Montero1, 2, 3, R. Sommer3,M. Augustin3, C. Blome3, R. Cabeza Martínez4, C. Horcajada Reales5, M. Alsina Gibert6, R. Ramón Sapena7, A. Peral Vázquez1, 2, J. Montoro López1, 2, S. Guisado Mun ̃oz1, 2, L. Pérez Jerónimo1, 2, P. de la Cueva Dobao1, 2, N. Kressel3, N. Mohr3

1Servicio de Dermatología, Hospital Universitario Infanta Leonor, Madrid, Spain

2Centro de Especialidades Vicente Soldevilla, Hospital Virgen de la Torre, Madrid, Spain

3German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

4Servicio de Dermatología, Hospital Universitario Puerta de Hierro-Majadahonda (HUPHM), Madrid, Spain

5Servicio de Dermatología, Hospital Universitario de Fuenlabrada, Madrid, Spain

6Servicio de Dermatología, Hospital Clinic de Barcelona, Barcelona, Spain

7Servicio de Dermatología, Hospital General Universitario de Alicante, Alicante, Spain

Actas Dermosifiliogr (Engl Ed). 2021 Jan;112(1):44-51

 

Background and aims: The Wound-QoL is a validated and feasible questionnaire for measuring disease-specific health-related quality of life in chronic wounds, originally developed for use in German.

The objective of this study was to translate the Wound-QoL for use in clinical care and in clinical trials in Spain and to validate this version.

PMID:
Epub 2020 Nov 1. 33137321
DOI:
10.1016/j.ad.2020.09.007

Assessment of stigma related to visible skin diseases: a systematic review and evaluation of patient-reported outcome measures

C. Luck-Sikorski1, P. Roßmann1, J. Topp2, M. Augustin2, R. Sommer2, N.A. Weinberger1

1Research Group: Chronic Diseases and Psychological health (COPE), University of Applied Health Sciences SRH Gera, Gera, Germany

2Institute for Health Services Research in Dermatology and Nursing (IVDP), German Centre for Health Services Research in Dermatology (CVderm), University Medical Centre Hamburg-Eppendorf (UKE), Hamburg, Germany

J Eur Acad Dermatol Venereol. 2021 Nov 24

 

Misconceptions about visible skin diseases are widespread, and patients often face discrimination and stigmatization due to their condition. The associated negative health and psychosocial consequences of stigmatization in skin diseases have prompted an increase in research activity in recent times, resulting in a wide variety of assessment measures. This study aimed at aggregating and evaluating evidence of psychometric properties and methodological quality of published measures to assess stigma in visible skin diseases.

PMID:
Epub ahead of print. 34817889
DOI:
10.1111/jdv.17833

Assessing the quality of life of people with chronic wounds by using the cross-culturally valid and revised Wound-QoL questionnaire

C.C. von Stülpnagel1, N. da Silva1, M. Augustin1, C. van Montfrans2, C. Fife3,4, A-M. Fagerdahl5, A. Gamus6, T. M. Klein1, C. Blome1, R. Sommer1

1German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg- Eppendorf (UKE), Hamburg, Germany

2Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands

3Baylor College of Medicine, Houston, Texas 4The U.S. Wound Registry, Woodlands, Texas

5Department of Clinical Science and Education, Wound Centre, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

6Maccabi Health Services, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Wound Repair Regen. 2021 May;29(3):452-459

 

The Wound-QoL is an often used reliable and valid measure, originally developed in Germany. It has been sequentially translated and validated for other languages/coun- tries, for the measurement of health-related quality of life (HRQoL) in patients with chronic wounds. However, a study from the United States postulated its benefits from further adaptations. Furthermore, some patients struggled to provide an answer for some of the items. We aimed to test the cross-cultural structure and psychometric per- formance of the questionnaire to suggest necessary revisions.

PMID:
Epub 2021 Feb 17. 33595907
DOI:
10.1111/wrr.12901

Interpersonal experiences of stigmatization and sexual impairments, quality of life and depression in patients with psoriasis: The mediating role of social avoidance coping

N. da Silva, M. Augustin, D. Wilsmann-Theis, P. Staubach-Renz, C. von Stülpnagel (2021, September-October).

ePoster presented at 30th European Academy of Dermatology and Venereology (EADV) Congress [Virtual].

<< < 1 2 3 > >>